Polyelectrolyte biomaterial interactions provide nanoparticulate carrier for oral insulin delivery.
Nanospheres are being developed for the oral delivery of peptide-based drugs such as insulin. Mucoadhesive, biodegradable, biocompatible, and acid-protective biomaterials are described using a combination of natural polyelectrolytes, with particles formulated through nanoemulsion dispersion followed by triggered in situ gel complexation. Biomaterials meeting these criteria include alginate, dextran, chitosan, and albumin in which alginate/dextran forms the core matrix complexed with chitosan and albumin coat. Smaller size and higher albumin-based acid-protective formulation was orally administered to diabetic rats and glucose reduction and physiological response analyzed. Insulin encapsulation efficiency was 90, 82, and 66% for uncoated, chitosan-coated, and albumin-chitosan-coated alginate nanospheres, respectively. The choice of coating polymer seems to influence insulin release profile and to be crucial to prevent peptic digestion. Physiological response following oral delivery showed that insulin albumin-chitosan-coated alginate nanospheres reduced glycemia approximately 72% of basal values. Albumin serves as an important enteric coating providing acid- and protease protection enabling uptake of active drug following oral dosage.
Reis
Catarina Pinto
CP
Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Portugal. catarinareis@ci.uc.pt
Ribeiro
António J
AJ
Veiga
Francisco
F
Neufeld
Ronald J
RJ
Damgé
Christiane
C
D000418:Albumins / Q000737:chemistry; D000464:Alginates; D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry*; D002152:Calorimetry, Differential Scanning; D048271:Chitosan; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004573:Electrolytes / Q000737:chemistry; D005079:Excipients; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D008297:Male; D053758:Nanoparticles; D010316:Particle Size; D010434:Pepsin A / Q000737:chemistry; D011108:Polymers / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D014783:Viscosity
D000418:Albumins; D000464:Alginates; D001672:Biocompatible Materials; D004337:Drug Carriers; D004573:Electrolytes; D005079:Excipients; D007004:Hypoglycemic Agents; D007328:Insulin; D011108:Polymers; D048271:Chitosan; D010434:Pepsin A